Acne vulgaris. acne vulgaris
Conditions
Interventions
Intervention 1: decuttane - isotretinoin 20 mg daily + Azithromycin 250 mg capsules three times a week, erythromycin solution of 4% once a day, oil-free sunscreen and Tcc soap three months. Interventi
Treatment - Drugs
decuttane - isotretinoin 20 mg daily + Azithromycin 250 mg capsules three times a week, erythromycin solution of 4% once a day, oil-free sunscreen and Tcc soap three months
Cyproterone Compound + Azithromycin 250 mg capsules three times a week, erythromycin solution of 4% once a day, oil-free sunscreen and Tcc soap three months
Sponsors
Isfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
14 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age between 14-45 years old; besides acne hirsutism (Ferriman & Gallwey score greater than or equal to 4) and Ludwing grade one or higher female androgenetic alopecia; absence of contraindications to treatment with tablets decuttane and CYPROTERONE COMPOUND based on questionnaire; not wanting to at least 9 months of pregnancy, or breast-feeding; individual patients signed a consent form Exclusion criteria: drug allergy; pregnancy or lactation; uncooperative patient or patient's consent to continue reading.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of acne vulgaris lesions. Timepoint: Baseline, three months and one month after the end of treatment. Method of measurement: Indices are calculated based on the Total Acne lesion Count( TLC) and acne severity index (ASI) for each patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of drug. Timepoint: Every 6 weeks. Method of measurement: clinical evaluation-liver function test and lipid profile. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Kioumars Jamshidi
Isfahan University of Medical Sciences
Outcome results
None listed